Oncology startup Volastra Therapeutics inked a deal with Microsoft to develop unique digital pathology tools for oncology and also announced the New York-based company’s seed funding round was extended from $12 million to $44 million.
Breast cancer overtook lung cancer as the most common form of the disease, accounting for nearly 12% of new cases each year worldwide, the World Health Organization said.
A roundup of biopharma news and updates includes Merck and Eisai’s Keytruda-Lenvima combo hitting the mark in a Phase III study for advanced endometrial cancer.
BioSpace reviews some of the more interesting recently published scientific studies, including whether the Covid-19 virus relieve pain.
Celyad Oncology is at the forefront of cutting-edge immunotherapy and is hopeful of providing a new way forward for patients with relapsed/refractory multiple myeloma.
South San Francisco-based Freenome closed on an oversubscribed $270 million Series C financing, with the round led by new investor Bain Capital Life Sciences and existing investor Perceptive Advisors.
Recently published scientific studies include research into whether Covid-19 immunity might not be possible.
The U.S. Food and Drug Administration approved Merck’s anti-PD-1 therapy Keytruda as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
AstraZeneca and Daiichi Sankyo’s Enhertu helped patients with three different types of cancer live longer in trials, pointing to potential broader use of the breast cancer treatment.
Merck’s checkpoint inhibitor Keytruda (pembrolizumab) hit one of the coprimary endpoints early in the Phase III KEYNOTE-177 clinical trial for a highly mutating form of colorectal cancer.